In its annual R&D briefing to investors today,
It's this scientific capability and diverse portfolio that positioned the company to quickly respond to the COVID-19 public health crisis.
'CSL's acumen in vaccines, monoclonal antibodies, recombinant technologies, manufacturing capabilities and external partnerships, along with a therapeutic area focus and insight that includes Immunology and Respiratory, has supported the growth and progress of our pipeline and has also enabled us to respond quickly to the need for potential solutions in the world's fight against COVID-19,' said
The company's efforts in the fight against COVID-19 include: Accelerating the development, manufacture and distribution of a vaccine candidate pioneered by researchers at the
Co-founding the
Developing an investigational, anti-SARS-CoV-2 plasma hyperimmune product for the Australian market to treat people with serious complications of COVID-19. The company is currently manufacturing its therapy for the clinical trial.
Conducting a Phase 2 study to assess the safety and efficacy of garadacimab (Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia. The first patient was enrolled in July.
Additionally, the company is partnering with SAb Biotherapeutics to manufacture clinical and early commercial supplies of
'The same collaborative mindset with which CSL has responded to the COVID-19 pandemic is also reflected in how we are advancing our pipeline,' said
About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
Contact:
Tel: 610 906 4564
Email: Greg.Healy@cslbehring.com
(C) 2020 Electronic News Publishing, source